Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Reexamination Certificate
2000-08-01
2003-02-18
Hartley, Michael G. (Department: 1616)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
C424S009363, C424S009364, C424S009365, C424S009600
Reexamination Certificate
active
06521209
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to optically active magnetic resonance imaging agents.
BACKGROUND OF THE INVENTION
Magnetic resonance imaging (MRI) is a clinical diagnostic and research procedure that uses a high-strength magnet and radio-frequency signals to produce images. The most abundant molecular species in biological tissues is water. It is the quantum mechanical “spin” of the water proton nuclei that ultimately gives rise to the signal in imaging experiments. In MRI the sample to be imaged is placed in a strong static magnetic field (1-12 Tesla) and the spins are excited with a pulse of radio frequency (RF) radiation to produce a net magnetization in the sample. Various magnetic field gradients and other RF pulses then act on the spins to code spatial information into the recorded signals. MRI is able to generate structural information in three dimensions in relatively short time spans.
There is rapidly growing body of literature demonstrating the clinical effectiveness of paramagnetic contrast agents; currently there are at least eight different contrast agents in clinical trials or in use. These agents provide further contrast, and thus enhanced images, wherever the contrast agent is found. For example, the approved contrast agents outlined below may be injected into the circulatory system and used to visualize vascular structures and abnormalities, amongst other things. The capacity to differentiate regions or tissues that may be magnetically similar but histologically different is a major impetus for the preparation of these agents.
The lanthanide atom Gd(III), has generally been chosen as the metal atom for contrast agents because it has a high magnetic moment (&mgr;
2
=63BM
2
), a symmetric electronic ground state, (S
8
), the largest paramagnetic dipole and the greatest paramagnetic relaxivity of any element. Gd(III) is rendered nontoxic by chelation. To date, a number of chelators have been used, including diethylenetriaminepentaacetic (DTPA), 1,4,7,10-tetraazacyclododecane′-N,N′N″,N′″-tetracetic acid (DOTA), and derivatives thereof See U.S. Pat. Nos. 5,155,215, 5,087,440, 5,219,553, 5,188,816, 4,885,363, 5,358,704, 5,262,532, and Meyer et al., Invest. Radiol. 25: S53 (1990).
The stability constant (K) for Gd(DTPA) is very high (logk=22.4) and is more commonly known as the formation constant (the higher the logk, the more stable the complex). This thermodynamic parameter indicates the fraction of Gd(III) ions that are in the unbound state will be quite small and should not be confused with the rate (kinetic stability) at which the loss of metal occurs. The water soluble Gd(DTPA)-chelate is stable, nontoxic, and one of the most widely used contrast enhancement agents in experimental and clinical imaging research. It was approved for clinical use in adult patients in June of 1988. It is an extracellular agent that accumulates in tissue by perfusion dominated processes. Image enhancement improvements using Gd(DTPA) are well documented in a number of applications (Runge et al., Magn, Reson. Imag. 3:85 (1991); Russell et al., AJR 152:813 (1989); Meyer et al., Invest. Radiol. 25:S53 (1990)) including visualizing blood-brain barrier disruptions caused by space occupying lesions and detection of abnormal vascularity. It has recently been applied to the functional mapping of the human visual cortex by defining regional cerebral hemodynarnics (Belliveau et al., (1991) 254:719).
Another chelator used in Gd contrast agents is the macrocyclic ligand 1,4,7,10-tetraazacyclododecane-N,N′,N″N′″-tetracetic acid (DOTA). The Gd-DOTA complex has been thoroughly studied in laboratory tests involving animals and humans. The complex is conformationally rigid, has an extremely high formation constant (logK=28.5), and at physiological pH possess very slow dissociation kinetics. Recently, the GdDOTA complex was approved as an MRI contrast agent for use in adults and infants in France and has been administered to over 4500 patients.
Another technique for imaging cells, frequently used in developmental biology, uses optical dyes, i.e. photoluminescent compounds, to visualize both subcellular and extracellular structures, as well as developmental cell lineages.
It is an object of the invention to provide bifunctional detection agents that can simultaneously behave as both an optical dye as well as an MRI contrast agent. Such agents can be visualized using either MRI and common optical (photoluminescent) techniques.
SUMMARY OF THE INVENTION
In accordance with the objects outlined above, the present invention provides bifunctional detection agents comprising optical dyes covalently linked to at least one magnetic resonance image (MRI) contrast agent. These agents mar include a linker, which may be either a coupling moiety or a polymer. These bifunctional detection agents include agents having the structure depicted below:
wherein
X is a coupling moiety and R is a substitution moiety.
The invention also provides bifunctional detection agents having the structure:
wherein
X is a coupling moiety and R is a substitution moiety.
The invention additionally provides bifunctional detection agents having the structure:
The invention further provides bifunctional detection agent comprising a polymer covalently linked to at least one optical dye and at least one MRI contrast agent. The polymer may comprise a polyamino acid. The polymer may have a molecular weight of less than 40 kD, 25 kD, 15 kD, or 10 kD.
The invention further provides methods of visualizing cells and tissues comprising the administration of the bifunctional detection agents with fluorescence and MRI detection.
REFERENCES:
patent: 4637988 (1987-01-01), Hinshaw et al.
patent: 4647447 (1987-03-01), Gries et al.
patent: 4678667 (1987-07-01), Meares et al.
patent: 4822594 (1989-04-01), Gibby
patent: 4837169 (1989-06-01), Toner
patent: 4877872 (1989-10-01), Morgan
patent: 4885363 (1989-12-01), Tweedle et al.
patent: 5087440 (1992-02-01), Cacheris et al.
patent: 5095099 (1992-03-01), Parkinson et al.
patent: 5133956 (1992-07-01), Garlich et al.
patent: 5155215 (1992-10-01), Ranney
patent: 5188816 (1993-02-01), Sherry et al.
patent: 5219553 (1993-06-01), Kraft et al.
patent: 5230882 (1993-07-01), Kornguth et al.
patent: 5256395 (1993-10-01), Barbet et al.
patent: 5262532 (1993-11-01), Tweedle et al.
patent: 5292414 (1994-03-01), Sessler et al.
patent: 5310539 (1994-05-01), Williams
patent: 5322681 (1994-06-01), Klaveness
patent: 5332567 (1994-07-01), Goldenberg
patent: 5338532 (1994-08-01), Tomalia et al.
patent: 5358704 (1994-10-01), Desreux et al.
patent: 5407657 (1995-04-01), Unger et al.
patent: 5419893 (1995-05-01), Berg et al.
patent: 5446145 (1995-08-01), Love et al.
patent: 5466438 (1995-11-01), Unger et al.
patent: 5466439 (1995-11-01), Gibby et al.
patent: 5531978 (1996-07-01), Berg et al.
patent: 5554748 (1996-09-01), Sieving et al.
patent: 5622821 (1997-04-01), Selvin et al.
patent: 5707605 (1998-01-01), Meade et al.
patent: 5914095 (1999-06-01), Watson
patent: 5955605 (1999-09-01), Axworthy et al.
patent: 5980862 (1999-11-01), Meade et al.
patent: 2197074 (1994-08-01), None
patent: 2139374 (1995-07-01), None
patent: WO 90/12050 (1990-10-01), None
patent: WO 92/19264 (1992-11-01), None
patent: 95/20981 (1995-08-01), None
patent: WO 95/27705 (1995-10-01), None
patent: WO 95/28966 (1995-11-01), None
patent: WO 95/31444 (1995-11-01), None
patent: WO 95/32741 (1995-12-01), None
patent: WO 96/23526 (1996-08-01), None
patent: WO 96/38184 (1996-12-01), None
patent: WO 97/21431 (1997-06-01), None
patent: WO 97/32862 (1997-09-01), None
patent: WO 97/36619 (1997-10-01), None
patent: WO 99/21592 (1999-05-01), None
Jacobs and Fraser, “Magnetic Resonance Microscopy of Embryonic Cell Lineages and Movements,”Science263:681-684 (1994).
Staubli and Meade, “The Design and Synthesis of Fluorescently Detectable Magnetic Resonance imaging Agents for Embryonic Cell Linage Analysis,”American Chemistry Society: Division of Inorganic Chemistry, 209th ACS National
Fraser Scott E.
Jacobs Russell E.
Meade Thomas J.
Dorsey & Whitney
Hartley Michael G.
Silva Robin M.
Trecartin Richard F.
LandOfFree
Bifunctional detection agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bifunctional detection agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bifunctional detection agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3127471